文献速递临床试验与 GCP真实世界研究与卫生经济

皮肤科护士主导的患者支持干预改善银屑病局部用药长期依从性:随机对照试验方案

Long-term improvement of psoriasis patients' adherence to topical drugs: testing a patient-supporting intervention delivered by healthcare professionals.
PubMed 文献 · Trials · 2021-10-25

BACKGROUND: Psoriasis affects 2-4% of the Western adult population and is a socio-economic burden for patients and society. Topical drugs are recommended as first-line treatment for mild-to-moderate psoriasis, but low adherence is a barrier to treatment success.…

要点

  • 干预由同一皮肤科护士定期提供提醒系统、问责、强化和信任建立支持。
  • 主要结局为Lattice-System医师整体评估的银屑病严重度变化。
  • 次要结局包括健康相关生活质量、初级和次级依从性及卫生经济学评价。

核心结论

  • 该研究旨在检验皮肤科护士主导的患者支持干预能否降低银屑病严重度、改善局部用药并具成本效果,目前尚无结果。

研究设计与样本

  • 随机对照试验,48周,中重度银屑病(累及≥4%体表面积)且18-85岁、处方局部治疗者随机分为非干预组(n≈57)和干预组(n≈57)。

关键数值与推荐

  • 干预组由三名经验丰富的皮肤科护士提供定期咨询支持,聚焦提醒系统、问责、强化和建立治疗信任,每位患者全程由同一护士支持。
  • 两组均处方含皮质类固醇和/或卡泊三醇的局部制剂。
  • 主要结局为Lattice-System医师整体评估的银屑病严重度降低。
  • 次要结局包括疾病特异和通用问卷测量的健康相关生活质量、初级依从性(已配药处方比例)和客观次级依从性(称重药包所得局部药物消耗率与估计推荐消耗比较)。
  • 计划开展卫生经济学评价,基于国家健康登记处报告的健康成本和干预成本进行成本效用和成本效果分析。

临床怎么用

  • 若干预显著降低银屑病严重度且经济性优于标准治疗,则可能可在皮肤科诊所实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis affects 2-4% of the Western adult population and is a socio-economic burden for patients and society. Topical drugs are recommended as first-line treatment for mild-to-moderate psoriasis, but low adherence is a barrier to treatment success. Psoriasis patients require support, in order to improve their long-term use of topical drugs. The project aims to test whether a patient-supporting intervention delivered by dermatology nurses can reduce the severity of psoriasis, improve the use of topical drugs, and is cost-effective compared to standard procedure. METHODS: The intervention consists of improved support delivered to patients by three experienced dermatology nurses, who will support patients on a regular basis by consultations with a focus on providing reminder systems, accountability, reinforcement, and building trust in the treatment. Each patient will be supported by the same dermatology nurse throughout the entire study period. The effect will be compared with standard procedure. The intervention will be tested in a randomized controlled trial during a 48-week period. A group of patients with moderate-to-severe psoriasis (psoriasis affecting ≥ 4% of the total body surface area) and 18-85 years of age who are prescribed topical treatment will be randomized to a non-intervention (n ≈ 57) or intervention group (n ≈ 57). Participants in both arms will be prescribed topical preparations containing corticosteroid and/or calcipotriol. The primary outcome will be a change in the severity of psoriasis, measured as reduction in the Lattice-System Physician's Global Assessment. Secondary outcomes will include changes in health-related quality of life (measured by disease specific and generic questionnaires), primary adherence (i.e., proportion of filled prescriptions), and secondary adherence by objective measure (rate of topical drug consumption (obtained by weighing medication packages) compared to estimated recommended consumption). A health economic evaluation is planned to run alongside the trial. Participants' total health costs will be estimated on the basis of health costs reported to the national health registries and costs spent on the intervention, after which a cost-utility and cost-effectiveness analysis will be carried out. DISCUSSION: If the intervention can reduce the severity of psoriasis in a significant manner and is economically favorable compared to standard treatment, there is potential for implementing the intervention in dermatology clinics. TRIAL REGISTRATION: Clinicaltrials.gov NCT04220554 . Registered on January 7, 2020. Study results, either positive, negative, or inconclusive, will be published on www.clinicaltrials.gov . Trial registration no. with the Danish Regional Committee on Health Research Ethics, registration no. 72613.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Svendsen MT, Feldman SR, Möller S, et al. Long-term improvement of psoriasis patients' adherence to topical drugs: testing a patient-supporting intervention delivered by healthcare professionals. Trials. 2021. PMID: 34696820. doi:10.1186/s13063-021-05707-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。